Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives $49.17 Average Price Target from Analysts

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year […]

Related Keywords

Canada ,United States ,Patrickd Yeramian ,Jamesm Frates , ,Amylyx Pharmaceuticals Price Performance ,Citigroup ,Securities Exchange Commission ,News Ratings For Amylyx Pharmaceuticals Daily ,Insider Activity At Amylyx Pharmaceuticals ,Ameriprise Financial Inc ,Amylyx Pharmaceuticals Inc ,Analyst Recommendations For Amylyx Pharmaceuticals ,Putnam Investments ,Squarepoint Ops ,Jpmorgan Chase Co ,Prelude Capital Management ,Amylyx Pharmaceuticals ,Nasdaq ,Get Free Report ,Exchange Commission ,Capital Management ,Get Free ,Amylyx Pharmaceuticals Daily ,